Sudo Biosciences is a biopharmaceutical company committed to designing and developing novel, best-in-class medicines to transform patients’ lives.
Location: United States, California, Menlo Park
Employees: 11-50
Total raised: $300M
Founded date: 2021
Investors 1
| Date | Name | Website |
| - | Frazier Li... | frazierls.... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 13.02.2024 | Series B | $147M | - |
| 02.01.2024 | Series B | $116M | - |
| 29.09.2022 | Series A | $37M | - |
Mentions in press and media 9
| Date | Title | Description |
| 28.10.2025 | Sudo Biosciences Announces Positive Phase 1 Results for Brain-Penetrant Allosteric TYK2 Inhibitor SUDO-550 | CARMEL, Indiana & LONDON — Sudo Biosciences, (“Sudo”), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced positive topline results from its Phas... |
| 20.03.2025 | British investment firm secures $250M to help fund development of new dementia therapeutics | British investment firm SV Health Investors has secured $250 million to go toward the development of first-in-class therapeutics for dementia, the second such fund the venture capitalists have put together. The final push past the finish li... |
| 13.02.2024 | Sudo Biosciences Raises Additional $30M in Series B; Brought Total Round to $147M | Sudo Biosciences, a Carmel, IN-based biopharmaceutical company committed to designing and developing precision TYK2 (tyrosine kinase 2) inhibitors, raised additional $30M in Series B funding. The round, which brought the total amount to $14... |
| 13.02.2024 | Sudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147M | CARMEL, IN - Sudo Biosciences (“Sudo”), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced that during January 2024, it completed a second close of ... |
| 20.12.2023 | Sudo Biosciences Raises $116M Series B | CARMEL, IN, Sudo Biosciences announced the close of a $116 million Series B financing round co-led by Enavate Sciences and TPG. >> Click here for more funding data on Sudo Biosciences >> To export Sudo Biosciences funding da... |
| 20.12.2023 | Sudo Biosciences Raises $116M in Series B Financing | Sudo Biosciences, a Carmel, IN-based biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, raised $116M in Series B funding. The round, which brought the total amount to... |
| 29.09.2022 | Sudo Biosciences Raises $37M in Series A Financing | Sudo Biosciences, a Menlo Park, CA-based biopharmaceutical company, raised $37M in Series A funding. The round was led by Frazier Life Sciences with participation from Velosity Capital. The company intends to use the funds to advance its le... |
| 28.09.2022 | Sudo Biosciences Scores $37M Series A | MENLO PARK, CA, Sudo Biosciences, a biopharmaceutical company, announced the close of $37M in Series A financing led by Frazier Life Sciences and Velosity Capital. >> Click here for more funding data on Sudo Biosciences >> T... |
| - | Sudo Biosciences | “Sudo Biosciences is a biopharmaceutical company committed to designing and developing novel, best-in-class medicines to transform patients’ lives.” |